Categorized | Stock Profiles

CBIS (Cannabis Science, Inc.)


cbis logoCannabis Science Inc. (CBIS) is a pioneer biotech company who uses cannabinoid science to develop cannabinoid-based extra formulas for various medical conditions, including over eight different formulas for Cancer.

As one of the first cannabinoid company to be publicly on the market, CBIS aims to provide innovative therapeutic solutions for current unmet medical needs through its cannabinoid-based formulations, as it has been known to be used as “folk medicine” for thousands of years in China, India, and the Middle East. It is not until recently, that anyone knew how or why cannabinoids worked but have yet proven to treat pain, migraine headaches, insomnia, nausea, depression, menstrual cramps, high blood pressure, anxiety, loss of appetite, epileptic seizures, Parkinson’s, glaucoma, chronic heartburn, and irritable bowel syndrome.

CBIS’s formulation have earned the company hundreds of millions of dollars in revenue and earning potential wherefore the company actively researches multiples strains of cannabis and European Union certified hemp varieties to select the best strains for creating a solution to critical ailments such as neurological disorders and cancer. Currently, the company is working at a facility in Spain and is collaborating with a local partner to initiate an agricultural program to conduct scientific testing of the revolutionary extracts for future clinical use. However, there is a current pre-clinical study being conducted at the prestigious Institute for Research , Hospitalization, and Health Care on Ageing in Italy for a thorough study on the efficacy of a cannabinoid formulation for sleep disorders and other neurobehavioral diseases.

Furthermore, CBIS is bringing its scientific studies overseas and is currently in final negotiations to establish the company’s first medical cannabis facility, including dispensaries and growing operations, in Canada. Likewise, the company is in final negotiations to acquire a Canadian based medical marijuana company who is already providing medical cannabis to patients under Canada’s regulations and will collaborate with medical doctors for additional cannabinoid research and trials. This operation could come at no better time as the company is receiving encouragement by the state of Florida who has currently turned in favor of cannabis for medical purposes.


Symbol: CBIS  [ Current PPS: $0.071  Outstanding Shares: 846.4M   Float: 24M  –  a/o September 15, 2014 ]

cbis chart




  • The cannabinoid market is estimated to total $30-$50 billion however, based on the Federal Medical Cannabis Program internal estimates believe the market will actually be worth $74 billion in 2017.
  • Cannabinoids have been found to aid AIDS/HIV, Alzheimers, Asthma, AutoimmuneDisease, Cancer, Crohn’s Disease, Diabetes, Digestive Disover, Gastro Intestinal (GERD), Glaucoma, High Blood Pressure, Influenza, Multiple Sclerosis, Pain Management, and Tourette Syndrome
  • Research Analysts predict the Global HIV Drugs Market to reach a $15.5 billion market value by 2014
  • Global Alzheimer’s Disease Treatment is said to reach $9 billion by 2016
  • By 2014, the Asthma and COPD drugs market will increase to $31 billion
  • The market for Diabetes medicine is forecasted to approach $65 billion by 2020.
  • Global Glaucoma Pharmaceuticals is predicted to exceed $3.35 billion by 2015
  • The use of cannabis as a natural remedy is said to have begun over 4,000 years ago and has since then been utilized as a globally known medicine specifically in China, India, and the Middle East to treat malaria, rheumatism, and constipation.
  • The Medical Marijuana Market is a $40 billion per year industry with some internal estimates placing it over $100 billion
  • The renowned Dr. Oz and CNN Dr. Sanjay Gupta have become recent supporters of Medical Marijuana
  • New York has become the 23rd state to approve medical marijuana
  • The U.S House and Senate is currently aiming to change the medical cannabis laws
  • The New York Times recently released an article comparing the medical marijuana market as the new “repealing prohibition” era.


Recent News

  • CBIS has appointed retired U.S Assistant Surgeon General, Dr. Roscoe M. Moore Jr., for a second term on the Scientific Advisory Board.
  • The company will sponsor the 3rd International Conference on Cannabinoids in Medicine that will be held in Strasbourg, France.
  • CBIS has also increased its equity in a Michigan-based company who is the leading resource for legislative initiative and management consulting for cannabinoid-based drug development, nutraceutical, cosmeceuticals, food products, and food supplments.


Get Updates on CBIS and other Hot Penny Stocks by Signing Up to our Free E-mail Newsletter!

This post was written by:

- who has written 2169 posts on StockRockandRoll.

Contact the author

Comments are closed.

© 2022 MJ Capital, LLC | All rights reserved